Covalent binding – Vividion

Still today, there are many proteins that are known and well-described drivers of cancer but so far it was impossible to target them with current anti-cancer therapies, which is why they are called “undruggable”. The latest developments in biomedical sciences and digital technologies are now opening up new opportunities to change this.

In 2021, with the acquisition of Vividion, a U.S.-headquartered biopharmaceutical company, we strengthened our precision drug discovery capabilities with a cutting-edge chemoproteomics platform. Vividion’s unique approach utilizes novel discovery technologies to unlock high value, previously unknown binding pockets in traditionally undruggable targets to generate first-in-class precision therapeutics in indications of high unmet medical need.